HY2Care Overview

  • Founded
  • 2014
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $4.15M
Latest Deal Amount
  • Investors
  • 5

HY2Care General Information


Developer of a medical device intended to repair cartilage defects. The company's product is a two-component injectable and bioresorbable hydrogel which are composed of a mixture of natural polymer conjugates that cross-link in a mild enzymatic reaction, enabling people to get access to a medical product which aims at functional repair of cartilage defects in the knee.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
  • ZH143
  • Drienerlolaan 5
  • 7522 NB Enschede
  • Netherlands
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

HY2Care Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 30-Apr-2019 $4.15M 00.000 Completed Generating Revenue
3. Grant 04-Aug-2016 000.00 000.00 Completed Generating Revenue
2. Grant $16.2K Completed Generating Revenue
1. Accelerator/Incubator 13-Apr-2015 $16.2K $16.2K Completed Generating Revenue
To view HY2Care’s complete valuation and funding history, request access »

HY2Care Executive Team (3)

Name Title Board Seat Contact Info
Leo Smit Chief Executive Officer
Chris Cardinaels Co-Founder
Marcel Karperien Chief Scientific Officer & Co-Founder
To view HY2Care’s complete executive team members history, request access »

HY2Care Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Brightlands Venture Partners Venture Capital Minority 000 0000 000000 0
ReumaNederland Other Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Startupbootcamp Accelerator/Incubator Minority 000 0000 000000 0
Lifesciences@work Other Minority 000 0000 000000 0
To view HY2Care’s complete investors history, request access »